Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial

Eitemau Tebyg

• Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)
  gan: Koshizaka, Masaya, et al.
  Cyhoeddwyd: (2017)
• Sitagliptin Successfully Ameliorates Glycemic Control in Werner Syndrome With Diabetes
  gan: Kitamoto, Takumi, et al.
  Cyhoeddwyd: (2012)
• Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
  gan: Davis, Joseph A., et al.
  Cyhoeddwyd: (2010)
• Sitagliptin Improves Postprandial Hyperglycemia by Inhibiting Glucagon Secretion in Werner Syndrome With Diabetes
  gan: Watanabe, Kaneyuki, et al.
  Cyhoeddwyd: (2013)
• The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
  gan: Kubota, Yoshiaki, et al.
  Cyhoeddwyd: (2012)